Drug Action
Triamcinolone exerts predominantly glucocorticoid effects with minimal mineralcorticoid effect.
PDF page 740
Loading InternPractice…
Drug reference
Triamcinolone exerts predominantly glucocorticoid effects with minimal mineralcorticoid effect.
PDF page 740
Suppression of inflammatory and allergic disorders ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 40 mg (max. per dose 100 mg), repeated if necessary, dose given for depot effect, to be administered into gluteal muscle; repeated at intervals according to patient’s response
PDF page 740
High dosage (may cause proximal myopathy), avoid in chronic therapy
PDF page 740
→Appendix 1: corticosteroids
PDF page 740
▶Uncommon Dizziness. flushing. hyperglycaemia
PDF page 740
There can be variation in the licensing of different medicines containing the same drug. Suspension for injection CAUTIONARY AND ADVISORY LABELS 10 EXCIPIENTS: May contain Benzyl alcohol ▶Adcortyl Intra-articular / Intradermal (Bristol-Myers Squibb Pharmaceuticals Ltd) Triamcinolone acetonide 10 mg per 1 ml Adcortyl Intra-articular / Intradermal 50mg/5ml suspension for injection vials | 1 vial P £3.63 DT = £3.63 Adcortyl Intra-articular / Intradermal 10mg/1ml suspension for injection ampoules | 5 ampoule P £4.47 DT = £4.47 ▶Kenalog (Bristol-Myers Squibb Pharmaceuticals Ltd) Triamcinolone acetonide 40 mg per 1 ml Kenalog Intra-articular / Intramuscular 40mg/1ml suspension for injection vials | 5 vial P £7.45 DT = £7.45 2.1 Cushing’s syndrome and disease Cushing’s Syndrome Management Most types of Cushing’s syndrome are treated surgically, that which occasionally accompanies carcinoma of the bronchus is not usually amenable to surgery. Metyrapone p. 719 has been found helpful in controlling the symptoms of the disease; it is also used in other forms of Cushing’s syndrome to prepare the patient for surgery. The dosages of metyrapone used are either low, and tailored to cortisol production, or high, in which case corticosteroid replacement therapy is also needed. Ketoconazole below may have a direct effect on corticotropic tumour cells in patients with Cushing’s disease. It is used under specialist supervision for treatment of endogenous Cushing’s syndrome. Other drugs used for Cushing’s syndrome and disease Pasireotide, p. 1003 ENZYME INHIBITORS
PDF page 740
Patient counselling is advised for triamcinolone acetonide injection (steroid card).
PDF page 740
40 mg (max. per dose 100 mg), repeated if
First-line fragment. Read the complete Indications and Dose section above.
PDF page 740